Last reviewed · How we verify
MEDI--522
At a glance
| Generic name | MEDI--522 |
|---|---|
| Sponsor | MedImmune LLC |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma (PHASE1)
- Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer (PHASE1, PHASE2)
- Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer (PHASE1, PHASE2)
- Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma (PHASE1)
- Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis (PHASE2)
- Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors (PHASE1)
- Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer (PHASE1, PHASE2)
- MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEDI--522 CI brief — competitive landscape report
- MEDI--522 updates RSS · CI watch RSS
- MedImmune LLC portfolio CI